Skip to main content

Table 2 Lung cancer stage stratified by subtypes and years

From: Collateral effects of the coronavirus disease 2019 pandemic on lung cancer diagnosis in Korea

Lung cancer subtype Stage Total P value*
NSCLC Stage I–II Stage III–IV   0.011
 2017 (Feb–Jun) 51 (42.1%) 70 (57.9%) 121  
 2018 (Feb–Jun) 41 (33.3%) 82 (66.7%) 123  
 2019 (Feb–Jun) 53 (37.3%) 89 (62.7% 142  
 2020 (Feb–Jun) 37 (25.3%) 109 (74.7%) 146  
 Total (Feb–Jun) 182 (34.2%) 350 (65.8%) 532  
SCLC Limited disease Extensive disease   0.239
 2017 (Feb–Jun) 5 (29.4%) 12 (70.6%) 17  
 2018 (Feb–Jun) 4 (25%) 12 (75%) 16  
 2019 (Feb–Jun) 5 (20.8%) 19 (79.2%) 24  
 2020 (Feb–Jun) 11 (47.8%) 12 (52.2%) 23  
 Total (Feb–Jun) 25 (31.3%) 55 (68.8%) 80  
  1. NSCLC non-small cell lung cancer, SCLC small cell lung cancer
  2. *Statistical significance was tested by the linear by linear association
\